Tigecycline, a broad-spectrum antibiotic that has become a workhorse in intensive care units around the world, may carry a heavier price than many clinicians realize. A new retrospective cohort study published in BMC Infectious Diseases by researchers at Xiangya Hospital of Central South University in Changsha, China, provides some of the clearest evidence yet that the concentration of the drug circulating in a patient’s blood is a powerful predictor of hypofibrinogenemia, a potentially dangerous depletion of fibrinogen, the essential protein that allows blood to clot. Among 148 patients with measurable tigecycline plasma concentrations, 85, or 57.43 percent, developed tigecycline-induced hypofibrinogenemia, a rate that underscores how common this complication is in the very population most vulnerable to its consequences.
Fibrinogen sits at the heart of hemostasis. When blood vessels are injured, the enzyme thrombin cleaves fibrinogen into fibrin strands, which weave together into the meshwork of a stable clot. When fibrinogen levels fall below roughly 2.0 grams per liter, the threshold the researchers used to define hypofibrinogenemia in this study, that meshwork becomes fragile or fails to form at all, leaving patients exposed to bleeding risks at a time when many are already fighting severe, multidrug-resistant infections. The problem for clinicians has long been that hypofibrinogenemia in intensive care patients has many potential causes, including sepsis itself, disseminated intravascular coagulation, liver dysfunction, and massive transfusion, making it difficult to know when the antibiotic rather than the underlying illness is to blame.
The research team, led by Xiong Guo, Yao Zhang, Tao Yin, and corresponding author Ping Wang, addressed this ambiguity by focusing on the tigecycline trough concentration, the lowest level of the drug in plasma, measured just before the next dose is administered. Trough concentrations are a cornerstone of therapeutic drug monitoring because they capture the baseline exposure a patient carries between doses. Patients treated between January 2018 and May 2026 were enrolled, and every case of hypofibrinogenemia was adjudicated using WHO-UMC causality criteria, a standardized pharmacovigilance framework that helps separate drug-induced adverse events from those attributable to disease processes. Patients were then divided into a hypofibrinogenemia group and a normal group based on their fibrinogen measurements.
Using multivariable logistic regression, a statistical technique that isolates the independent contribution of each factor while controlling for the others, the team identified three independent risk factors for developing the complication: baseline fibrinogen level, duration of tigecycline treatment, and, critically, the trough concentration of the drug itself. Baseline fibrinogen carried a p-value of 0.022, treatment duration a p-value of 0.007, and trough concentration a p-value of 0.026, all of which reached conventional thresholds of statistical significance. Receiver operating characteristic analysis, which evaluates how well a continuous variable discriminates between patients who do and do not experience an outcome, then translated these risk factors into practical clinical cutoffs. Patients with a trough concentration of 0.27 micrograms per milliliter or higher, a treatment duration of 6.50 days or longer, or a baseline fibrinogen below 4.55 grams per liter faced markedly elevated risk.
Perhaps the most striking finding emerged when the investigators sorted patients into quartiles according to their trough concentrations. The incidence of hypofibrinogenemia rose in a clean, stepwise gradient across the quartiles, climbing from 36.11 percent in the lowest quartile to 82.05 percent in the highest, with a p-value for trend below 0.001. This dose-response relationship is exactly the kind of biological signal that lends credibility to a causal association: as exposure to the drug increases, so does the probability of harm, in a predictable and monotonic fashion. For intensive care physicians, the implication is that a simple blood measurement, available through routine therapeutic drug monitoring, could flag patients heading toward a coagulation crisis before fibrinogen levels collapse.
Beyond establishing who is at risk, the study mapped the natural history of the complication in unusual detail. The median time from the start of therapy to the onset of hypofibrinogenemia was 7 days, meaning clinicians should not assume that early uneventful treatment rules the risk out. Once established, the median duration of hypofibrinogenemia was 6 days. Most reassuring, however, was the recovery phase: after tigecycline was discontinued, fibrinogen levels returned to normal within a median of just 2.5 days. This rapid rebound suggests that the drug’s effect on fibrinogen is, at least in most patients, reversible rather than a sign of lasting injury to the synthetic machinery of the liver, which produces the vast majority of circulating fibrinogen.
The correlation analysis revealed an intriguing internal logic to the recovery process. Fibrinogen recovery time after discontinuation of tigecycline was positively correlated with both the time to hypofibrinogenemia onset and the duration of the hypofibrinogenemia episode, with both correlations reaching a p-value of 0.004. In other words, patients whose fibrinogen fell early, and those whose levels remained suppressed for longer, also took longer to bounce back once the drug was withdrawn. This pattern hints at a cumulative exposure phenomenon: the deeper and more prolonged the disruption, the more time the body’s fibrinogen production requires to restore equilibrium. It also reinforces the practical value of early detection, since patients identified and managed before prolonged suppression sets in may recover faster.
Importantly, the researchers also examined whether hypofibrinogenemia translated into worse short-term survival. Using Cox regression, they assessed 30-day mortality and found no significant association between the complication and death within a month, with a p-value of 0.289. That null finding should not be read as license for complacency, the study’s structure suggests, because the enrolled patients were already among the sickest in the hospital, with severe infections caused by multidrug-resistant pathogens, and competing risks in such a population can obscure the specific contribution of any single complication. Nevertheless, the result provides useful context: tigecycline-induced hypofibrinogenemia appears to be a common and monitorable adverse effect whose clinical management can focus on surveillance and timely drug withdrawal rather than panic.
The mechanistic story behind these observations remains an open question, and the authors are careful not to overclaim. Tigecycline is extensively metabolized and cleared through the liver and biliary system, and previous reports have linked the drug to elevations in liver enzymes, bilirubin, and coagulation parameters including prothrombin time and the international normalized ratio. One plausible explanation is that high cumulative exposure interferes directly or indirectly with hepatic fibrinogen synthesis, or with the clotting cascade more broadly, though the precise molecular pathway has not been pinned down. What the new study adds is a quantitative framework: a specific trough concentration threshold, a specific treatment duration, and a specific baseline fibrinogen level that together allow clinicians to stratify risk before the complication develops.
For the growing field of therapeutic drug monitoring in critical care, the findings carry a broader message. Antibiotics are often dosed by standard weight-based formulas that ignore the enormous pharmacokinetic variability among critically ill patients, whose organ function, fluid status, and protein binding can swing dramatically from day to day. Tigecycline, despite its approval and widespread use against serious Gram-positive and Gram-negative infections, has no well-established therapeutic range for safety, and this study suggests that establishing one could prevent a substantial burden of harm. The work was supported by the Hunan Natural Science Foundation, and the team notes that the risk gradient across concentration quartiles was prominent and progressive. If future prospective studies confirm the cutoffs identified here, routine trough measurement could become as standard a part of tigecycline therapy as the drug’s acclaimed antimicrobial coverage, turning an invisible pharmacokinetic variable into an actionable shield for patients who have little physiological reserve left to spare.
One reason trough monitoring may be especially informative for tigecycline lies in the drug’s unusual pharmacokinetic profile. Unlike most antibiotics, tigecycline distributes extensively into tissues, yielding a large volume of distribution and plasma concentrations that are only a small fraction of total body exposure. Critically ill patients are notoriously variable in this regard: shifts in fluid balance, hypoalbuminemia, hepatic congestion, and evolving organ dysfunction can all reshape how the drug behaves in a given individual, so two patients receiving the same weight-based dose may carry very different internal exposures. A trough measurement offers a practical window into that variability at the bedside.
The choice of a 2.0 grams per liter fibrinogen threshold also deserves comment. Fibrinogen is an acute-phase reactant, meaning it typically rises during inflammation, so many patients with severe infections start therapy with elevated levels. This may explain why a baseline value below 4.55 grams per liter emerged as a risk factor: patients whose fibrinogen reserves are already modest have less buffer before drug-related suppression pushes them into the hypofibrinogenemic range. It also complicates interpretation, since a falling fibrinogen in an inflamed patient may still represent a meaningful decline even if the absolute value remains above conventional cutoffs.
As a retrospective, single-center analysis, the study has inherent limitations that temper broad generalization. Concentration measurements were obtained as part of routine care rather than a standardized sampling protocol, and unmeasured confounders such as concurrent transfusions, blood products, or other fibrinogen-lowering drugs cannot be fully excluded. The authors’ use of WHO-UMC adjudication mitigates but does not eliminate this concern. Nevertheless, the open-access dataset, the dose-response gradient, and the internally consistent timing relationships provide a solid foundation for the prospective validation studies that would be needed before the proposed cutoffs enter routine clinical practice.
Subject of Research: The association between tigecycline trough plasma concentration and tigecycline-induced hypofibrinogenemia in critically ill patients.
Article Title: Tigecycline trough concentration and its relationship with hypofibrinogenemia: from onset and duration to recovery
Article References: Guo, X., Zhang, Y., Yin, T., & Wang, P. (2026). Tigecycline trough concentration and its relationship with hypofibrinogenemia: from onset and duration to recovery. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14419-8
Image Credits: AI Generated
DOI: 10.1186/s12879-026-14419-8
Keywords: tigecycline, hypofibrinogenemia, trough concentration, therapeutic drug monitoring, fibrinogen, intensive care unit, antibiotic adverse effects, coagulation, multidrug-resistant infections, pharmacokinetics, drug safety, BMC Infectious Diseases
Cite Scienmag News
APA MLA Chicago
Ophelia Keating. (September 12, 2026). Blood Drug Levels Predict Dangerous Clotting Complication from Hospital Antibiotic Tigecycline. Scienmag. https://scienmag.com/blood-drug-levels-predict-dangerous-clotting-complication-from-hospital-antibiotic-tigecycline/
Ophelia Keating. “Blood Drug Levels Predict Dangerous Clotting Complication from Hospital Antibiotic Tigecycline.” Scienmag, 12 September 2026, https://scienmag.com/blood-drug-levels-predict-dangerous-clotting-complication-from-hospital-antibiotic-tigecycline/. Accessed 12 September 2026.
Ophelia Keating. “Blood Drug Levels Predict Dangerous Clotting Complication from Hospital Antibiotic Tigecycline.” Scienmag. September 12, 2026. https://scienmag.com/blood-drug-levels-predict-dangerous-clotting-complication-from-hospital-antibiotic-tigecycline/
Copy citation Download RIS
Tags: antibiotic adverse effectsantibiotic blood concentrationantibiotic-related bleeding risksblood clotting and antibiotic therapyblood clotting disorder predictorsblood drug levelsBMC Infectious Diseasescoagulationdrug safetyfibrinogenfibrinogen depletion in ICU patientshemostasis disruption from antibioticshypofibrinogenemiaintensive care unitmultidrug-resistant infectionsPharmacokineticsretrospective cohort study on tigecyclinerisk of blood clotting complicationssevere infection treatment side effectstherapeutic drug monitoringtigecyclinetigecycline plasma concentration monitoringtigecycline-induced hypofibrinogenemiatrough concentration
